Supplementary Methods. Supplementary Tables S1-7. Supplementary Figures S1 and S2 from Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
crossref(2023)
摘要
Supplementary Tables S1-7. Supplementary Table S1. Clinical characteristics of patients in the present analysis. Supplementary Table S2. Plasma/tissue concordance results for del19 and L858R mutations. Supplementary Table S3. EGFR mutations identified in tissue and plasma by the cobas® EGFR mutation test. Supplementary Table S4. Concordance between tumor and BEAMing plasma EGFR status. Supplementary Table S5. Overall concordance between cobas® and BEAMing EGFR mutation tests. Supplementary Table S6. Platform Comparison of T790M tests in a sample set enriched for low copy plasma cases. Supplementary Table S7. EGFR mutation detection by cobas® plasma test and NSCLC disease classification (n = 72) Supplementary Figures S1-2. Supplementary Figure S1. Tumor burden is a weak predictor of ability to detect EGFR mutations in plasma. Supplementary Figure S2. T790M to activating mutation ratio in plasma is associated with depth of response to rociletinib.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要